Journal
NATURE CANCER
Volume 3, Issue 1, Pages 60-+Publisher
NATURE PORTFOLIO
DOI: 10.1038/s43018-021-00280-y
Keywords
-
Categories
Funding
- Brewster Foundation
- Breast Cancer Research Foundation
- National Institutes of Health [R01CA134519]
- Department of Defense Breast Cancer Research Program [BC151403]
- American Cancer Society
- Susan G. Komen [PDF17332118]
- NJCCR [DFHS15PPCO21]
- Preclinical Imaging and Flow Cytometry Shared Resources of the Rutgers Cancer Institute of New Jersey [P30CA072720]
- Susan G. Komen Foundation
- Ludwig Cancer Research
Ask authors/readers for more resources
By targeting the MTDH-SND1 interaction through genetic and pharmacological approaches, it has been found that the complex plays a crucial role in suppressing antitumor T cell responses in breast cancer, ultimately enhancing immune surveillance and sensitivity to anti-programmed cell death protein 1 therapy. This suggests that combination therapy could be a viable approach to increase immune-checkpoint blockade therapy responses in metastatic breast cancer, providing a potential new strategy for treatment.
Despite increased overall survival rates, curative options for metastatic breast cancer remain limited. We have previously shown that metadherin (MTDH) is frequently overexpressed in poor prognosis breast cancer, where it promotes metastasis and therapy resistance through its interaction with staphylococcal nuclease domain-containing 1 (SND1). Through genetic and pharmacological targeting of the MTDH-SND1 interaction, we reveal a key role for this complex in suppressing antitumor T cell responses in breast cancer. The MTDH-SND1 complex reduces tumor antigen presentation and inhibits T cell infiltration and activation by binding to and destabilizing Tap1/2 messenger RNAs, which encode key components of the antigen-presentation machinery. Following small-molecule compound C26-A6 treatment to disrupt the MTDH-SND1 complex, we showed enhanced immune surveillance and sensitivity to anti-programmed cell death protein 1 therapy in preclinical models of metastatic breast cancer, in support of this combination therapy as a viable approach to increase immune-checkpoint blockade therapy responses in metastatic breast cancer. Kang and colleagues demonstrate that pharmacological targeting of the MTDH1-SND1 axis prevents immune evasion during metastatic progression and provides a synergistic combination strategy with immune-checkpoint blockade to treat metastasis.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available